Should I buy or sell Zai Lab stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks .

What is Zai Lab's stock price target for 2024?

4 analysts have issued 1 year target prices for Zai Lab's stock. Their ZLAB share price targets range from $62.50 to $128.00. On average, they anticipate the company's stock price to reach $79.97 in the next twelve months. This suggests a possible upside of 190.8% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts .

How have ZLAB shares performed in 2023?

Zai Lab's stock was trading at $30.70 at the start of the year. Since then, ZLAB shares have decreased by 10.4% and is now trading at $27.50. View the best growth stocks for 2023 here .

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our ZLAB earnings forecast .

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $69.23 million for the quarter, compared to the consensus estimate of $67.12 million. Zai Lab had a negative trailing twelve-month return on equity of 31.19% and a negative net margin of 114.22%.

What ETFs hold Zai Lab's stock?

ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB) , ETFMG Treatments Testing and Advancements ETF (GERM) , ALPS Medical Breakthroughs ETF (SBIO) , Virtus LifeSci Biotech Products ETF (BBP) , Loncar China Biopharma ETF (CHNA) , Fidelity Disruptive Medicine ETF (FMED) and Invesco Golden Dragon China ETF (PGJ) and

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA) , CRISPR Therapeutics (CRSP) , Inseego (INSG) , Niu Technologies (NIU) , JD.com (JD) , Bilibili (BILI) , Marvell Technology (MRVL) , Baidu (BIDU) , BioXcel Therapeutics (BTAI) and Baozun (BZUN) .

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different institutional and retail investors. Top institutional investors include Invesco Ltd. (3.25%), Wellington Management Group LLP (1.95%), Segantii Capital Management Ltd (1.81%), Bamco Inc. NY (1.60%), FMR LLC (1.28%) and Rock Springs Capital Management LP (1.25%). Insiders that own company stock include Frazor Titus Edmondson III , Harald Reinhart , John D Diekman, John D Diekman , Joshua L Smiley, Kai-Xian Chen , Peter Wirth , Tao Fu , William Ki Chul Cho , William Lis , Yajing Chen and Ying Du . View institutional ownership trends .

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Zai Lab Stock Price, News & Analysis (NASDAQ:ZLAB)

$27.50

+0.21 (+0.77%)

(As of 12/1/2023 ET)

Compare

Today's Range: $26.57
▼
$28.03
50-Day Range: $22.97
▼
$30.01
52-Week Range: $22.35
▼
$49.81

Volume: 509,301 shs
Average Volume: 388,930 shs
Market Capitalization: $2.72 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $79.97

Zai Lab MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 190.8% Upside
$79.97 Price Target
Short Interest: Bearish
4.10% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.45
Based on 13 Articles This Week
Insider Trading: Acquiring Shares
$134,650 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.48) to ($2.84) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

506th out of 953 stocks

Pharmaceutical Preparations Industry

239th out of 448 stocks

3.5

Analyst's Opinion

Consensus Rating
Zai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $79.97, Zai Lab has a forecasted upside of 190.8% from its current price of $27.50.
Amount of Analyst Coverage
Zai Lab has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.10% of the outstanding shares of Zai Lab have been sold short.
Short Interest Ratio / Days to Cover
Zai Lab has a short interest ratio ("days to cover") of 9.5.
Change versus previous month
Short interest in Zai Lab has recently increased by 7.43%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Zai Lab does not currently pay a dividend.
Dividend Growth
Zai Lab does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZLAB.

2.5

News and Social Media Coverage

News Sentiment
Zai Lab has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Zai Lab this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for ZLAB on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zai Lab insiders have bought 3,134.45% more of their company's stock than they have sold. Specifically, they have bought $134,650.00 in company stock and sold $4,163.00 in company stock.
Percentage Held by Insiders
Only 5.23% of the stock of Zai Lab is held by insiders.
Percentage Held by Institutions
43.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Zai Lab are expected to grow in the coming year, from ($3.48) to ($2.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zai Lab is -8.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zai Lab is -8.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zai Lab has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zai Lab Stock (NASDAQ:ZLAB)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZLAB Stock News Headlines

December 2, 2023 | americanbankingnews.com

FY2024 Earnings Forecast for Zai Lab Limited Issued By Leerink Partnrs (NASDAQ:ZLAB)

December 1, 2023 | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Price Target Raised to $66.00 at JPMorgan Chase & Co.

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 1, 2023 | americanbankingnews.com

Zai Lab Limited (NASDAQ:ZLAB) Expected to Post Q1 2024 Earnings of ($0.74) Per Share

November 30, 2023 | markets.businessinsider.com

Analyst Ratings for Zai Lab

November 27, 2023 | msn.com

Zai Lab Limited - ADR (ZLAB) Price Target Increased by 9.31% to 32.49

November 26, 2023 | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Shares Up 4.4%

November 19, 2023 | seekingalpha.com

Zai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade)

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 17, 2023 | msn.com

Zai Lab executive purchases 5,000 shares

November 17, 2023 | finance.yahoo.com

Institutional investors may adopt severe steps after Zai Lab Limited's (NASDAQ:ZLAB) latest 6.3% drop adds to a year losses

November 10, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Technology Stocks: Zai Lab (ZLAB), Navitas Semiconductor (NVTS)

November 9, 2023 | finance.yahoo.com

Zai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Call Transcript

November 8, 2023 | finanznachrichten.de

Zai Lab Limited: Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

November 7, 2023 | finance.yahoo.com

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

November 7, 2023 | benzinga.com

Recap: Zai Lab Q3 Earnings

November 7, 2023 | finance.yahoo.com

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

November 6, 2023 | uk.finance.yahoo.com

Zai Lab Ltd (1ZLB.SG)

November 3, 2023 | msn.com

Zai Lab Limited - ADR (ZLAB) Price Target Increased by 5.97% to 29.72

October 26, 2023 | markets.businessinsider.com

Goldman Sachs Maintains Buy Rating for Zai Lab: Here's What You Need To Know

October 23, 2023 | finance.yahoo.com

Further weakness as Zai Lab (NASDAQ:ZLAB) drops 4.5% this week, taking three-year losses to 72%

October 18, 2023 | finance.yahoo.com

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023

October 18, 2023 | markets.businessinsider.com

Strong Drug Sales and Market Position Drive Buy Rating for Zai Lab: An In-depth Analysis

October 17, 2023 | benzinga.com

The Latest Analyst Ratings for Zai Lab

October 17, 2023 | finance.yahoo.com

Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?

September 18, 2023 | finance.yahoo.com

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China

September 7, 2023 | seekingalpha.com

Zai Lab Stock: De-Risking Through Market Tapping

See More Headlines

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ZLAB
CUSIP: N/A
CIK: 1704292
Web: www.zailaboratory.com
Phone: 862161632588
Fax: 86-21-6163-2570
Employees: 2,036
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $79.97
High Stock Price Target: $128.00
Low Stock Price Target: $62.50
Potential Upside/Downside: +190.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-443,290,000.00
Net Margins: -114.22%
Pretax Margin: -114.22%
Return on Equity: -31.19%
Return on Assets: -26.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.68
Quick Ratio: 7.33

Sales & Book Value

Annual Sales: $215.04 million
Price / Sales: 12.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.91 per share
Price / Book: 3.09

Miscellaneous

Outstanding Shares: 98,840,000
Free Float: 93,670,000
Market Cap: $2.72 billion
Optionable: Optionable
Beta: 1.06

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Ying Du Ph.D. (Age 57)
Founder, Chairperson & CEO
Comp: $1.67M
Mr. Joshua L. Smiley (Age 53)
President & COO
Comp: $647.11k
Dr. Rafael G. Amado M.D. (Age 59)
President and Head of Global Oncology Research & Development
Comp: $477k
Dr. Harald Reinhart M.D. (Age 71)
President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases
Comp: $923.33k
Dr. Yajing Chen Ph.D.
Chief Financial Officer
Dr. Peter Huang Ph.D.
Chief Scientific Officer
Mr. Frazor Titus Edmondson III (Age 57)
J.D., Chief Legal Officer & Corporate Secretary
Comp: $829k
Ms. Ann E. Beasley J.D.
Chief Compliance Officer
Dr. Ning Xu M.D. (Age 58)
Executive VP & Head of Clinical Operations
Dr. Jonathan J. Wang MBA (Age 41)
Ph.D., Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZLAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings or view top-rated stocks.
What is Zai Lab's stock price target for 2024?: 4 analysts have issued 1 year target prices for Zai Lab's stock. Their ZLAB share price targets range from $62.50 to $128.00. On average, they anticipate the company's stock price to reach $79.97 in the next twelve months. This suggests a possible upside of 190.8% from the stock's current price.
View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts.
How have ZLAB shares performed in 2023?: Zai Lab's stock was trading at $30.70 at the start of the year. Since then, ZLAB shares have decreased by 10.4% and is now trading at $27.50.
View the best growth stocks for 2023 here.
When is Zai Lab's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our ZLAB earnings forecast.
How were Zai Lab's earnings last quarter?: Zai Lab Limited (NASDAQ:ZLAB) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $69.23 million for the quarter, compared to the consensus estimate of $67.12 million. Zai Lab had a negative trailing twelve-month return on equity of 31.19% and a negative net margin of 114.22%.
What ETFs hold Zai Lab's stock?: ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA), Fidelity Disruptive Medicine ETF (FMED) and Invesco Golden Dragon China ETF (PGJ) and

What other stocks do shareholders of Zai Lab own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).
When did Zai Lab IPO?: (ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.
Who are Zai Lab's major shareholders?: Zai Lab's stock is owned by many different institutional and retail investors. Top institutional investors include Invesco Ltd. (3.25%), Wellington Management Group LLP (1.95%), Segantii Capital Management Ltd (1.81%), Bamco Inc. NY (1.60%), FMR LLC (1.28%) and Rock Springs Capital Management LP (1.25%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Joshua L Smiley, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis, Yajing Chen and Ying Du.
View institutional ownership trends.
How do I buy shares of Zai Lab?: Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ZLAB) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial